A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors

Stopped early · Phase 1

Conditions studied: Advanced Solid Tumors

In brief

The purpose of this study is to determine if CVX-241 (PF-05057459) is safe and tolerable when given as weekly infusions to adult patients with advanced solid tumors.

Key facts

Study ID

NCT01004822

Run by

Pfizer

People needed

31

Starts

2010-03-01

Expected to finish

2014-05-01

Last updated by the study team

2015-11-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed solid tumors unresponsive to current therapy or for which there is no standard therapy.
• Stage 2 only: Histologically or cytologically documented EOC or PPC with < or equal to 3 previous anti-cancer therapies, but at least 1 prior platinum containing regimen.
• Adequate coagulation, liver, and renal function.
• Candidate for Dynamic Contrast-Enhanced Magnetic Resonance Imaging [DCE-MRI] evaluation
• Eastern Cooperative Oncology Group [ECOG] performance status of 0 or 1

You may not qualify if…

• History of clinically significant toxicity to Vascular Endothelial Growth Factor [VEGF] inhibition.
• Evidence of bleeding problems.
• Uncontrolled hypertension.
• Patients with primary brain cancer and/or non-small cell lung cancer of squamous cell histology

Where it is running

• Premiere Oncology of Arizona — Scottsdale, Arizona, United States
• Premiere Oncology, A Medical Corporation — Santa Monica, California, United States
• Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.